Core Viewpoint - The announcement highlights a significant collaboration between China Tongfu (01763) and Beijing Normal University, focusing on the patent transfer and academic-industry cooperation for the development of a new drug, Fluorine [F] Betazone, aimed at early diagnosis of Alzheimer's disease [1] Company Summary - China Tongfu's subsidiary, Atom High-Tech, signed a patent transfer agreement and an academic-industry cooperation agreement with Beijing Normal University on December 10, 2025 [1] - The Fluorine [F] Betazone project is a result of collaboration with Professor Cui Mengchao's team and is characterized by having complete independent intellectual property rights [1] - The drug shows significant improvement in clinical applications, demonstrating a notable reduction in non-specific uptake in brain white matter compared to similar products approved by the FDA [1] Industry Summary - The signing event represents a milestone in the collaboration between academia and industry, aimed at transforming scientific research outcomes into national strategic productivity [1] - The nuclear medicine industry is currently experiencing a golden development period, with Atom High-Tech positioned as a core player due to its deep industry experience and distinctive characteristics [1] - Future collaboration will focus on accelerating the clinical transformation of core results and building a talent cultivation pathway, contributing to global competition in new nuclear medicine technologies and supporting the high-quality development of China's nuclear medicine sector [1]
中国同辐(01763)：附属与北师大签署氟[18F]贝他嗪一类创新核药专利转让协议及产学研项目合作协议